Boceprevir, an anti SARS-CoV-2 drugs screened by artificial intelligence new drugs discovery platform, was once again confirmed by American scientists that its inhibitory effect was excellent
The novel coronavirus pneumonia outbreak has prompted scientists around the world to develop new anti SARS-CoV-2 drugs / vaccines at top speed. Recently, a study published in the journal Cell Research by the school of medicine of South Florida Health University and the school of pharmacy of the University of Arizona found that boceprevir could inhibit the replication of sars-cov-2 at the cell level (EC50: 1.31 ± 0.58 μ m). This is consistent with the in vitro antiviral activity test of boceprevir screened by smart pharmaceutical AI new drug discovery platform at the beginning of this year. (please click for details)
Boceprevir is a novel coronavirus pneumonia drug, and its effective dose, safety, formulation and human body handling of drugs (pharmacokinetics) are well known. This will greatly accelerate the steps needed for Boceprevir to carry out clinical trials of new crown pneumonia.
"New use of old drugs" is a common way to find drugs. AI assisted drug discovery platform has significant advantages in discovering new indications of old drugs. In the outbreak of novel coronavirus pneumonia, Chi Rui medical strategy used this strategy to identify potential effective drugs within one week and verify them.
(Docking simulation diagram of effective compounds screened by smart pharmaceutical AI platform and 3clpro protein)
(a. Darunavir；b. Bicyclol；c. Abacavir；d. Boceprevir)
(In vitro virus inhibition curve of effective drugs screened by smart pharmaceutical AI platform)